Universidad Peruana Cayetano Heredia
Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial
JavaScript is disabled for your browser. Some features of this site may not work without it.
Mostrar el registro sencillo del ítem
| dc.contributor.author | Soto, Alonso | |
| dc.contributor.author | Krapp, Fiorella | |
| dc.contributor.author | Vargas, Alex | |
| dc.contributor.author | Cabrejos, Lucía | |
| dc.contributor.author | Argumanis, Enrique | |
| dc.contributor.author | García, Patricia L. | |
| dc.contributor.author | Altamirano, Karina | |
| dc.contributor.author | Montes Delgado, Martin | |
| dc.contributor.author | Chacón Uscamaita, Pamela Roxana | |
| dc.contributor.author | Garcia Funegra, Patricia Jannet | |
| dc.date.accessioned | 2021-06-08T15:46:14Z | |
| dc.date.available | 2021-06-08T15:46:14Z | |
| dc.date.issued | 2021 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12866/9505 | |
| dc.description.abstract | Objectives: The general objective of this study is to test the hypothesis that administration of convalescent plasma from donors with previous diagnosis of severe COVID-19 pneumonia is safe and associated with a decrease in all-cause in-hospital mortality among hospitalized patients with COVID-19 at 30 days in comparison with standard treatment alone. The secondary objectives are as follows: (1) to assess the efficacy of convalescent plasma to reduce the length of hospitalization, (2) to assess the efficacy of convalescent plasma to reduce the length of ICU stay, and (3) to assess the efficacy of convalescent plasma on reducing the requirement of invasive mechanical ventilation or ICU stay.The secondary objectives are as follows: (1) to assess the efficacy of convalescent plasma to reduce the length of hospitalization, (2) to assess the efficacy of convalescent plasma to reduce the length of ICU stay, and (3) to assess the efficacy of convalescent plasma on reducing the requirement of invasive mechanical ventilation or ICU stay | en_US |
| dc.language.iso | eng | |
| dc.publisher | BioMed Central | |
| dc.relation.ispartofseries | Trials | |
| dc.rights | info:eu-repo/semantics/restrictedAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
| dc.subject | COVID-19 | en_US |
| dc.subject | Randomized controlled trial | en_US |
| dc.subject | Mortality | en_US |
| dc.subject | Protocol | en_US |
| dc.subject | Adverse reactions | en_US |
| dc.subject | Convalescent plasma | en_US |
| dc.subject | Safety | en_US |
| dc.title | Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial | en_US |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.doi | https://doi.org/10.1186/s13063-021-05189-6 | |
| dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.01.05 | |
| dc.relation.issn | 1745-6215 |
Ficheros en el ítem
| Ficheros | Tamaño | Formato | Ver |
|---|---|---|---|
|
No hay ficheros asociados a este ítem. |
|||
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Artículos en revistas indizadas [4988]
Recuperados de bases de datos bibliográficas
Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess
